Compounds > paclitaxel
Page last updated: 2024-08-23

paclitaxel and Cochlear Hearing Loss

paclitaxel has been researched along with Cochlear Hearing Loss in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Albuloushi, A; Lovgren, ML; Martin, PE; Steel, A; Waters, A; Yeoh, Y; Zamiri, M1
Aycicek, A; Bucak, A; Cangal, A; Gonul, Y; Ozdemir, C; Ulu, S; Uysal, M1
Carvalho, AL; Feher, O; Gomez, MV; Kowalski, LP; Liberman, PH; Pellizzon, AC; Schultz, C; Testa, JR1
Agca, O; Akyol, MU; Atas, A; Poyraz, A; Sarac, S1
Aghajanian, C; Almadrones, L; Fennelly, D; Gogas, H; Hoskins, WJ; Shapiro, F; Spriggs, DR1
Berrettini, S; De Vito, A; Pazzagli, I; Tibaldi, C1

Other Studies

6 other study(ies) available for paclitaxel and Cochlear Hearing Loss

ArticleYear
A heterozygous mutation in GJB2 (Cx26F142L) associated with deafness and recurrent skin rashes results in connexin assembly deficiencies.
    Experimental dermatology, 2020, Volume: 29, Issue:10

    Topics: Biological Transport; Carbenoxolone; Cell Survival; Child; Connexin 26; Connexin 43; Endoplasmic Reticulum Stress; Exanthema; Female; Gene Expression; HaCaT Cells; Hearing Loss, Sensorineural; HeLa Cells; Heterozygote; Humans; Microtubules; Mutation; Paclitaxel; Transfection; Tubulin Modulators

2020
Investigation of protective role of curcumin against paclitaxel-induced inner ear damage in rats.
    The Laryngoscope, 2015, Volume: 125, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Disease Models, Animal; Ear, Inner; Hearing Loss, Sensorineural; Otoacoustic Emissions, Spontaneous; Paclitaxel; Rats; Rats, Sprague-Dawley; Treatment Outcome

2015
Auditory effects after organ preservation protocol for laryngeal/hypopharyngeal carcinomas.
    Archives of otolaryngology--head & neck surgery, 2004, Volume: 130, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Audiometry, Pure-Tone; Auditory Threshold; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Hearing Loss, Sensorineural; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy; Radiotherapy Dosage

2004
Investigation of ototoxic effects of Taxol on a mice model.
    International journal of pediatric otorhinolaryngology, 2006, Volume: 70, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Auditory Threshold; Cochlea; Epithelial Cells; Fibroblasts; Hearing Loss, Sensorineural; Injections, Intraperitoneal; Mice; Models, Animal; Paclitaxel; Random Allocation; Vacuoles

2006
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer.
    Gynecologic oncology, 1996, Volume: 61, Issue:1

    Topics: Adult; Aged; Cisplatin; Diabetes Complications; Diabetic Neuropathies; Female; Hearing Loss, Sensorineural; Humans; Hyperglycemia; Kidney; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Sensation

1996
A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hearing Loss, Sensorineural; Humans; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine

1998